Abstract:
The effectiveness of the 3rd generation calcium channel blocker lercanidipine was evaluated in patients with isolated arterial hypertension of middle and elderly age.37 patients with ISH – 21 (57.1%) men and 16 (42.9%) women aged 40-75 years were examined. Patients of both clinical groups received lercanidipine at a dose of 10 mg / day once and with insufficient efficacy of therapy after 10 days, the dose of lercanidipine was increased to 20 mg / day. When analyzing the results 4 weeks after the start of treatment, significant improvement in well-being was noted in both groups of patients, the target level of SAD (less than 140 mmHg) was achieved in 11 (73.3%) and 15 (75%) patients, respectively. Improvement of the parameters of the daily blood pressure
profile was expressed in a decrease in patients of the 1st and 2nd groups of the level of SAD and the level of DAD. Also in reducing the variability of SADn.
